MIB‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy

The MIB‐1 labeling index, which is based on Ki67 immunostaining, is widely used to evaluate the proliferation of tumor cells in lymphoma. However, its clinical significance has not been fully assessed. We retrospectively evaluated the prognostic impact of the MIB‐1 labeling index at the time of diag...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Yamamoto, Eri, Tomita, Naoto, Sakata, Seiji, Tsuyama, Naoko, Takeuchi, Kengo, Nakajima, Yuki, Miyashita, Kazuho, Tachibana, Takayoshi, Takasaki, Hirotaka, Tanaka, Masatsugu, Hashimoto, Chizuko, Koharazawa, Hideyuki, Fujimaki, Katsumichi, Taguchi, Jun, Harano, Hiroshi, Motomura, Shigeki, Ishigatsubo, Yoshiaki
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2013
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653523/
https://ncbi.nlm.nih.gov/pubmed/24112697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12288
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares